BARD1 G320*

CI-VAR-00417002Explore in graph →CIViC 5573

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
BARD1 G320*	Carboplatin + GemcitabineCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID13253 A patient with lung adenocarcinoma harboring a somatic homozygous BARD1 G320* stop-gain alteration and an RBBP8 exon 3–4 duplication was classified as homologous recombination deficient by HRDetect an… (full text at CIViC) PMID 36964191 · Tsang et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.